These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 35780181)

  • 1. GBP3 promotes glioblastoma resistance to temozolomide by enhancing DNA damage repair.
    Xu H; Jin J; Chen Y; Wu G; Zhu H; Wang Q; Wang J; Li S; Grigore FN; Ma J; Chen CC; Lan Q; Li M
    Oncogene; 2022 Jul; 41(31):3876-3885. PubMed ID: 35780181
    [TBL] [Abstract][Full Text] [Related]  

  • 2. GBP3-STING interaction in glioblastoma coordinates autophagy, anti-oxidative, and DNA repair programs in response to temozolomide.
    Ma J; Wang Z; Chen CC; Li M
    Oncotarget; 2023 May; 14():483-484. PubMed ID: 37204260
    [No Abstract]   [Full Text] [Related]  

  • 3. Pharmacological inhibition of serine synthesis enhances temozolomide efficacy by decreasing O
    Jin L; Kiang KM; Cheng SY; Leung GK
    Lab Invest; 2022 Feb; 102(2):194-203. PubMed ID: 34625658
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Up-Regulation of Cyclooxygenase-2 (COX-2) Expression by Temozolomide (TMZ) in Human Glioblastoma (GBM) Cell Lines.
    Lombardi F; Augello FR; Artone S; Gugu MK; Cifone MG; Cinque B; Palumbo P
    Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35163465
    [TBL] [Abstract][Full Text] [Related]  

  • 5. IKBKE enhances TMZ-chemoresistance through upregulation of MGMT expression in glioblastoma.
    Guo G; Sun Y; Hong R; Xiong J; Lu Y; Liu Y; Lu J; Zhang Z; Guo C; Nan Y; Huang Q
    Clin Transl Oncol; 2020 Aug; 22(8):1252-1262. PubMed ID: 31865606
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A novel compound EPIC-0412 reverses temozolomide resistance via inhibiting DNA repair/MGMT in glioblastoma.
    Zhao J; Yang S; Cui X; Wang Q; Yang E; Tong F; Hong B; Xiao M; Xin L; Xu C; Tan Y; Kang C
    Neuro Oncol; 2023 May; 25(5):857-870. PubMed ID: 36272139
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The antagonistic effects of temozolomide and trichostatin a combination on MGMT and DNA mismatch repair pathways in Glioblastoma.
    Güven M; Taşpınar F; Denizler-Ebiri FN; Castresana JS; Taşpınar M
    Med Oncol; 2023 Jul; 40(8):223. PubMed ID: 37403006
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PARP-mediated PARylation of MGMT is critical to promote repair of temozolomide-induced O6-methylguanine DNA damage in glioblastoma.
    Wu S; Li X; Gao F; de Groot JF; Koul D; Yung WKA
    Neuro Oncol; 2021 Jun; 23(6):920-931. PubMed ID: 33433610
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A co-formulation of interferons type I and II enhances temozolomide response in glioblastoma with unmethylated MGMT promoter status.
    Vázquez-Blomquist D; Leenstra S; van der Kaaij M; Villarreal A; Bello-Rivero I
    Mol Biol Rep; 2020 Jul; 47(7):5263-5271. PubMed ID: 32607953
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lnc-TALC promotes O
    Wu P; Cai J; Chen Q; Han B; Meng X; Li Y; Li Z; Wang R; Lin L; Duan C; Kang C; Jiang C
    Nat Commun; 2019 May; 10(1):2045. PubMed ID: 31053733
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MEX3A Impairs DNA Mismatch Repair Signaling and Mediates Acquired Temozolomide Resistance in Glioblastoma.
    Gan T; Wang Y; Xie M; Wang Q; Zhao S; Wang P; Shi Q; Qian X; Miao F; Shen Z; Nie E
    Cancer Res; 2022 Nov; 82(22):4234-4246. PubMed ID: 36112059
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Regulation of temozolomide resistance in glioma cells via the RIP2/NF-κB/MGMT pathway.
    Hu YH; Jiao BH; Wang CY; Wu JL
    CNS Neurosci Ther; 2021 May; 27(5):552-563. PubMed ID: 33460245
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preconditioning with INC280 and LDK378 drugs sensitizes MGMT-unmethylated glioblastoma to temozolomide: Pre-clinical assessment.
    Das A; Alshareef M; Porto GBF; Infinger LK; Vandergrift WA; Lindhorst SM; Varma AK; Patel SJ; Cachia D
    J Neurol Sci; 2020 Nov; 418():117102. PubMed ID: 32866816
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of MGMT promoter methylation status and correlation with temozolomide response in orthotopic glioblastoma xenograft model.
    Kitange GJ; Carlson BL; Mladek AC; Decker PA; Schroeder MA; Wu W; Grogan PT; Giannini C; Ballman KV; Buckner JC; James CD; Sarkaria JN
    J Neurooncol; 2009 Mar; 92(1):23-31. PubMed ID: 19011762
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SNAP reverses temozolomide resistance in human glioblastoma multiforme cells through down-regulation of MGMT.
    Tsai CK; Huang LC; Wu YP; Kan IY; Hueng DY
    FASEB J; 2019 Dec; 33(12):14171-14184. PubMed ID: 31725331
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alkylpurine-DNA-N-glycosylase confers resistance to temozolomide in xenograft models of glioblastoma multiforme and is associated with poor survival in patients.
    Agnihotri S; Gajadhar AS; Ternamian C; Gorlia T; Diefes KL; Mischel PS; Kelly J; McGown G; Thorncroft M; Carlson BL; Sarkaria JN; Margison GP; Aldape K; Hawkins C; Hegi M; Guha A
    J Clin Invest; 2012 Jan; 122(1):253-66. PubMed ID: 22156195
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of NF-κB results in anti-glioma activity and reduces temozolomide-induced chemoresistance by down-regulating MGMT gene expression.
    Yu Z; Chen Y; Wang S; Li P; Zhou G; Yuan Y
    Cancer Lett; 2018 Aug; 428():77-89. PubMed ID: 29705182
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recycling of SLC38A1 to the plasma membrane by DSCR3 promotes acquired temozolomide resistance in glioblastoma.
    Lin R; Xu Y; Xie S; Zhang Y; Wang H; Yi GZ; Huang G; Ni B; Song H; Wang Z; Qi ST; Liu Y
    J Neurooncol; 2022 Mar; 157(1):15-26. PubMed ID: 35187626
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PARP‑1 inhibition sensitizes temozolomide‑treated glioblastoma cell lines and decreases drug resistance independent of MGMT activity and PTEN proficiency.
    Montaldi AP; Lima SCG; Godoy PRDV; Xavier DJ; Sakamoto-Hojo ET
    Oncol Rep; 2020 Nov; 44(5):2275-2287. PubMed ID: 32901889
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pulsed and Discontinuous Electromagnetic Field Exposure Decreases Temozolomide Resistance in Glioblastoma by Modulating the Expression of O
    Dehghani-Soltani S; Eftekhar-Vaghefi SH; Babaee A; Basiri M; Mohammadipoor-Ghasemabad L; Vosough P; Ahmadi-Zeidabadi M
    Cancer Biother Radiopharm; 2021 Sep; 36(7):579-587. PubMed ID: 32644826
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.